This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Pitavastatin calcium

Read time: 1 mins
Marketing start date: 18 Nov 2024
...
 

Summary of product characteristics


Effective Time

20231103

Version

4

Spl Product Data Elements

pitavastatin calcium pitavastatin calcium PITAVASTATIN CALCIUM PITAVASTATIN CALCIUM CARBONATE CROSPOVIDONE (120 .MU.M) HYPROMELLOSES LACTOSE MONOHYDRATE MAGNESIUM STEARATE SODIUM CARBONATE POLYETHYLENE GLYCOL, UNSPECIFIED TALC TITANIUM DIOXIDE WHITE TO OFF-WHITE ROUND 481 pitavastatin calcium pitavastatin calcium PITAVASTATIN CALCIUM PITAVASTATIN CALCIUM CARBONATE CROSPOVIDONE (120 .MU.M) HYPROMELLOSES LACTOSE MONOHYDRATE MAGNESIUM STEARATE SODIUM CARBONATE POLYETHYLENE GLYCOL, UNSPECIFIED TALC TITANIUM DIOXIDE WHITE TO OFF-WHITE ROUND 482 pitavastatin calcium pitavastatin calcium PITAVASTATIN CALCIUM PITAVASTATIN CALCIUM CARBONATE CROSPOVIDONE (120 .MU.M) HYPROMELLOSES LACTOSE MONOHYDRATE MAGNESIUM STEARATE SODIUM CARBONATE POLYETHYLENE GLYCOL, UNSPECIFIED TALC TITANIUM DIOXIDE WHITE TO OFF-WHITE ROUND 483

Application Number

ANDA206047

Brand Name

Pitavastatin calcium

Generic Name

pitavastatin calcium

Product Ndc

70771-1786

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Pitavastatin Tablets, 1 mg NDC 70771-1784-9 Bottle of 90 tablets Rx only Pitavastatin Tablets, 2 mg NDC 70771-1785-9 Bottle of 90 tablets Rx only Pitavastatin Tablets, 4 mg NDC 70771-1786-9 Bottle of 90 tablets Rx only 1 mg label 2 mg label 4 mg label

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.